Impact News +++ WDH: Düngerkonzern K+S engt Gewinnausblick für 2026 ein (DPA-AFX) +++ K+S Aktie -4,33%

COHERUS Aktie

>COHERUS Aktienkurs

0.762 EUR +4.5% (TradegateBSX)

Ask: 0.761 EUR / 2170 Stück

Bid: 0.721 EUR / 2082 Stück

Tagesumsatz: 75 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

COHERUS Aktie über LYNX handeln

Intraday

1 Jahr

>COHERUS Performance

1 Woche: +7,5%

1 Monat: -24,7%

3 Monate: -33,9%

6 Monate: -50,7%

1 Jahr: -36,8%

laufendes Jahr: -36,8%

>COHERUS Aktie

Profil:

Coherus Oncology, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative immuno-oncology therapies for cancer. The company’s current portfolio centers on LOQTORZI, an approved PD-1 inhibitor used i..
>Volltext..

Insiderhandel:

>COHERUS Kennzahlen

Aktien/ Unternehmen:

Analysten:

Bewertung:

Rentabilität:

Managementeffizenz:

>COHERUS Peer Group

Gesundheit, Antikörper- Behandlung, Onkologie/ Krebs- Behandlung

>COHERUS Chart & Kurs - NASDAQ

>COHERUS News

10.11.26 - 09:00	Coherus Oncology: 3 Key Takeaways for Long-Term Investors (Fool)
	With less than 12 months of cash on hand, the margin for error is thin, and the oncologist survey on LOQTORZI's standard-of-care status may matter as much as any cost cut....

10.11.26 - 08:36	Coherus Oncology (CHRS) Q3 2026 Earnings Call Transcript (Fool)
	Coherus cuts 30% of staff and narrows focus to esophageal cancer as cash runway tightens....

10.11.26 - 05:39	Coherus outlines $6M-$7M quarterly savings and lowers LOQTORZI cash-burn support target to $25M-$30M per quarter (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

10.11.26 - 02:30	Coherus Oncology (CHRS) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
	Coherus Oncology (CHRS) delivered earnings and revenue surprises of -13.64% and -10.25%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?...

10.11.26 - 00:12	Earnings Call: Coherus BioSciences verfehlt Umsatzerwartungen im 3. Quartal 2026 – Aktie legt dennoch zu (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

09.11.26 - 22:39	Coherus BioSciences Non-GAAP EPS of -$0.20 beats by $0.01, revenue of $14.27M misses by $1.66M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

09.11.26 - 22:09	Coherus Oncology Reports Third Quarter 2026 Financial Results and Announces Strategic Prioritization Plan (GlobeNewswire EN)
	– Focus development efforts on tagmokitug/toripalimab as a potential best-in-disease treatment for esophageal cancer with plans for expedited development – ...

08.11.26 - 23:42	Coherus BioSciences Q3 2026 Earnings Preview (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

02.11.26 - 17:30	Will Coherus Oncology (CHRS) Report Negative Earnings Next Week? What You Should Know (Zacks)
	Coherus Oncology (CHRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations....

28.10.26 - 21:39	Coherus releases promising early-stage data on tagmokitug in esophageal cancer (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

27.10.26 - 14:33	Coherus to Participate in Upcoming Investor Conferences (GlobeNewswire EN)
	REDWOOD CITY, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS), today announced that the company will be webcasting its participation in the following upcoming investor conferences:...

26.10.26 - 14:30

Coherus Oncology to Report Third Quarter 2026 Financial Results on November 9, 2026 (GlobeNewswire EN)

REDWOOD CITY, Calif., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today announced that its third quarter 2026 financial results will be released on Monday, November 9, 2026. Starting at 5:00 p.m. Eastern Daylight Time on November 9, 2026, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update....

14.10.26 - 22:30

Coherus Oncology to Host Webcast to Disclose Interim Tagmokitug Clinical Data on October 28, 2026 (GlobeNewswire EN)

REDWOOD CITY, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS) today announced that the Company will release interim clinical data related to its tagmokitug development program evaluating the cytolytic CCR8 antibody with toripalimab and multiple solid tumors on Wednesday, October 28, 2026. Coherus management will host a webcast from 4:30 p.m. to 6:00 p.m. Eastern Daylight Time to discuss the data and provide additional context. The company has invited key opinion leaders to join the webcast and provide their clinical perspective....

23.09.26 - 15:31	Coherus Oncology Retains Oppenheimer & Co. to Market Legacy BioSimilar Assets (GlobeNewswire EN)
	- Oppenheimer Initiates a Robust Process with Global Reach for the Benefit of Shareholders - - Oppenheimer Initiates a Robust Process with Global Reach for the Benefit of Shareholders -...

16.09.26 - 19:31	Coherus auf Morgan Stanley Konferenz: Onkologie-Strategie gewinnt an Dynamik (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

15.09.26 - 15:01	Coherus Oncology auf der Global Healthcare Conference: LOQTORZI-Umsätze sollen Pipeline finanzieren (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

13.08.26 - 02:36	Coherus Oncology (CHRS) Q2 2026 Earnings Call Transcript (Fool)
	LOQTORZI sales surged 37% year-over-year as clinical programs advance toward key data readouts....

06.08.26 - 01:45	Coherus Oncology (CHRS) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
	Coherus Oncology (CHRS) delivered earnings and revenue surprises of -337.50% and -45.57%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?...

05.08.26 - 22:30	Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire EN)
	– LOQTORZI® net revenue of $13.6 million in Q2 2026, up 15% over Q1 –...

22.07.26 - 19:39

Coherus Oncology to Report Second Quarter 2026 Financial Results on August 5, 2026 (GlobeNewswire EN)

REDWOOD CITY, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today announced that its second quarter 2026 financial results will be released on Wednesday, August 5, 2026. Starting at 5:00 p.m. Eastern Daylight Time on August 5, 2026, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update....

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Der Schönheit öffnet man jede Türe, vor der Wahrheit schlägt man sie zu. - Lisa Wenger

Partner: >TradegateBSX Börse | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram